GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer R...(GSK Cataloging this type of information...),Health

Date:6/20/2008

GSK, "Cataloging this type of information in a network like caBIG(TM) leads to a ready-made body of biologic information that can be mined by all cancer researchers to further everyone's understanding of cancer. In turn, we hope this data will further drive the identification of predictive biomarkers and lead to shorter, more directed clinical trials allowing us to bring drugs more quickly to patients who need them."

The genomic data being shared by GSK through caBIG(TM) come from cell lines derived from a wide variety of tumors, including breast, prostate, lung and ovarian cancers. Researchers at academic institutions, small research facilities and non-profit organizations may benefit by not having to incur the prohibitive cost and time involved in identifying and cataloging each cell line.

"The ability for researchers to share data via the caBIG(TM) network is exactly what this initiative was designed to enable," said Robert Clarke, Ph.D., D.Sc., professor of oncology and physiology and biophysics at the Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital. "As more scientists throughout the cancer community, in the US and globally, use caBIG(TM) and find it easy to share data and collaborate, both basic and clinical research will be improved. We're excited about what this cancer cell data might provide to other researchers and we also hope it will be a catalyst for other organizations to follow the GSK example."

The NCI launched the caBIG(TM) initiative in 2004 to accelerate the research and discovery of new approaches to the detection, diagnosis, treatment, and prevention of cancer. Since that time, more than 200 organizations and 1000 individuals have helped to create more than 40 biomedical research tools such as caArray, the microarray data management system that is guiding the annotation and supporting the exchange of the cancer cell array data provided by GSK.

Inte
'/>"/>

SOURCE GlaxoSmithKline Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA